Board of Directors

Ms. Babiak is a former Managing Partner at Ernst & Young LLP (EY), where she held a variety of roles with the firm in the United States and the United Kingdom from 1982 to 2009. After joining the firm’s audit practice in 1982 specializing in the audit of information systems, she was a founder of EY’s technology security and risk services practice in 1996, building and leading cyber and IT security, data analytics and technology risk practices in the Northern Europe, Middle East and India and Africa (NEMIA) region. She served as a Board Member and Managing Partner of Regulatory & Public Policy for the NEMIA region from July 2006 to July 2008, and as a founder and Global Leader of EY’s Climate Change and Sustainability Services practice from July 2008 to December 2009. Ms. Babiak has served on the board of directors of Bank of Montreal since October 2012. Previously, she served on the board of directors of Euromoney Institutional Investor PLC, an international business-information group listed on the London Stock Exchange, from December 2017 to November 2022; as a non-executive director of Royal Mail Holdings plc from March 2013 to April 2014 as it transitioned from government ownership to a FTSE 100-listed company; Experian plc from April 2014 to January 2016; and Logica plc from January 2010 until its sale in August 2012. She is a U.S.-qualified Certified Public Accountant (CPA), Certified Information Systems Auditor (CISA), and Certified Information Security Manager (CISM). She is also a Chartered Accountant (FCA), and a member of the Institute of Chartered Accountants in England and Wales (ICAEW), of which she served as a Council Member from 2011 until she reached the term limit in 2019.

Chris Bischoff is a managing director at General Catalyst, a venture capital firm that partners with founders from seed through growth stages and beyond to build companies that withstand the test of time. At GC, Chris focuses on investments in healthcare and fintech companies in the U.S and Europe. Based in London, Chris leads GC’s healthcare investment practice responsible for delivering on the promise of Health Assurance: the healthcare industry’s evolution from a “sick care” system to a resilient, proactive Health Assurance system designed to help people stay well, bend the cost curve, and make quality care more affordable and more accessible to all.

Prior to joining General Catalyst, Chris was senior investment director at Kinnevik (OTCMKTS: KNVKF), where he led the investment team and London office. Earlier in his career, Chris was Managing Director and Head of European Media and Internet at Goldman Sachs. Chris has led investments in category-defining companies including Aidoc, Avito, Babylon Health, Betterment, Cedar, CityBlock, Devoted Health, Livongo, Sword Health, Overjet and Village MD.

Chris holds an MBA from INSEAD and an MA from the University of Bristol.

David Brailer is known around the world for his leadership and entrepreneurialism in health care, particularly in the use of health information technology. Over the past three decades, Dr. Brailer has built a variety of private and public sector organizations. Dr. Brailer is currently Chairman of Health Evolution, a firm devoted to education of health care leaders, founded in 2011. Health Evolution enables leading health care organizations to adapt to rapidly changing forces in the health care industry and operates the renowned Health Evolution Summit.

From 2007 to 2017, Dr. David Brailer was a managing partner at HEP, a fund that invested in companies with the potential to transform health care delivery. Prior to HEP, Dr. Brailer was appointed by President George W. Bush as the nation’s first National Coordinator for Health Information Technology. In this role, Dr. Brailer oversaw development of the nation’s strategy for electronic records, information sharing, consumer empowerment and transformation of research and public health. His efforts set the foundation for the rapid adoption of digital health technologies that is underway today. From 1996 through 2002, Dr. Brailer was founder and CEO of CareScience, a health care information management company. Under his leadership, CareScience developed one of the nation’s earliest big data health care cloud solutions, serving more than 25 million patients in 200 major health care systems and physician groups across the United States. During Dr. Brailer’s leadership, CareScience raised private and public capital and develop numerous solution and technology platforms. Dr. Brailer holds doctoral degrees in medicine and economics. He earned his M.D. from West Virginia University and his Ph.D. in economics from The Wharton School. He became board certified in internal medicine after internship and residency at the Hospital of the University of Pennsylvania, and practiced in HIV medicine and immune deficiency until 2002. Dr. Brailer was appointed a Charles A. Dana Fellow and a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania. Dr. Brailer taught for a decade at The Wharton School, where he developed its curriculum on health information technology. Dr. Brailer serves on the Board of Directors of Walgreens (NASDAQ: WBA), where he chairs the company’s Finance Committee. He serves as a board member or chairman of five private health care companies.

Dr. Brailer is a member of the Health Care Policy Advisory Council at Harvard Medical School, the Advisory Board of the Margolis Center for Health Policy at Duke University and is Chairman of the Health Evolution Summit. Dr. Brailer grew up in a small town in rural West Virginia where his family has lived since 1840, and now lives in San Francisco with his spouse and two children.

John Driscoll, Executive Vice President and President, U.S. Healthcare, brings more than 25 years of health care experience to Walgreens Boots Alliance, Inc. Driscoll oversees U.S. Healthcare for WBA as the company expands into larger, faster-growing profit pools that drive synergies across the care continuum, including provider enablement and managed service organizations, primary care, population health, home health, post-acute care, specialty pharmacy and retail pharmacy.

Driscoll joined WBA in October 2022, when WBA entered into a definitive agreement to acquire full ownership of CareCentrix, where he served as Chief Executive Officer since 2013. CareCentrix is now an integral part of WBA’s U.S. Healthcare segment and the only independent, home-centered platform that coordinates care to the home for health plans, patients and providers.

Prior to CareCentrix, Driscoll served as President at Castlight Health, a healthcare technology company. Previously, he served as Group President for new markets at Medco. He also founded and chaired the Surescripts ePrescribing Network, building the first cross-industry collaborative with competing Retail, PBM, and Health Plans cooperating to revolutionize e-prescribing. 

Earlier in his career, Driscoll was a member of the executive team at Oxford Health Plans, serving as Corporate Vice President for government programs. In addition, he was selected by the White House for its Entrepreneurs in Residence program in 2011 to advise the Food and Drug Administration on new paths for innovation. He has a B.A. and M.B.A. from Harvard University, was a resident tutor at Winthrop House and holds an MPhil from Cambridge University in England. Driscoll served as a captain in the U.S. Army Reserve.

Ginger Graham is WBA Board Lead Independent Director. She has served on the WBA Board since 2010, and in October 2022, was named the Board’s Lead Independent Director. From November 2007 to December 2016, Ms. Graham advised numerous executives on building successful healthcare businesses as President and Chief Executive Officer of Two Trees Consulting, Inc. From 2003 to 2007, she was President and CEO of Amylin Pharmaceuticals, a biopharmaceutical company focused on first-in-class medicines for people with diabetes. Prior to that, Ms. Graham was Group Chairman, Office of the President for Guidant Corporation, a global leader in cardiology medical technology, which was recognized as one of Fortune’s “Best Companies to Work For in America” and one of IndustryWeek’s “100 Best Managed Companies in the World” during Ms. Graham’s tenure. Ms. Graham was on faculty at Harvard Business School from 2009 to 2012 and started her career at Eli Lilly and Company.

Ms. Graham served on the board of directors of Clovis Oncology, Inc. from 2013 to 2022. From 2018 to 2020, she served on the board of directors of Genomic Health, Inc. Ms. Graham sits on the advisory board for the Kellogg Center for Executive Women and is co-chair of the Center for Women’s Health Research at the University of Colorado. She has been recognized as one of PharmaVoice’s “100 Most Inspiring People” and one of World Pharmaceuticals’ “Top 40 Most Influential People” in the industry.

Annie Lamont is a Managing Partner of Oak HC/FT where she focuses on venture and growth equity opportunities in healthcare information services and financial services technology. Annie has been ranked as top investor on the Forbes Midas List and a Top 100 Venture Capitalist by CB Insights and The New York Times. She currently serves on the Boards of Aspire Health, Benefitfocus, Candescent Health, Freshbooks, Hometeam, Independent Living Systems, Poynt, Precision Medicine Group, Quartet, VillageMD and xG Health Solutions. Annie graduated from Stanford University.

Dr. Le Benger is the Interim President of VillageMD. He serves as Executive Chairman of the Summit Health and CityMD Board of Directors and previously held the role of Chief Executive Officer for Summit Health (previously Summit Medical Group) from 1999 to 2021. He is also an Ear, Nose, and Throat physician who specializes in head and neck oncologic surgery and is a fellow of the American Society of Head and Neck Surgery. Dr. Le Benger is a recipient of the MDx Medical, Inc. Patient's Choice Award, and has been included on the Jersey Choice Top Doctors, New Jersey Family New Jersey's Favorite Kids' Docs, and the NJBiz “Power 100” lists. 

Manmohan Mahajan is the Interim Global Chief Financial Officer of Walgreens Boots Alliance, Inc. He joined the company in 2016, and most recently served as Senior Vice President, Global Controller and Chief Accounting Officer, where he led global reporting, global finance systems and technical accounting teams, and also provided oversight to the controllership functions at Boots in the UK and Ireland, as well as Boots Opticians and International Retail. Prior to joining WBA, Mahajan worked at GE Capital for 13 years in roles of increasing responsibilities, including Controller at GE Capital Americas and Assistant Global Controller at GE Capital Commercial Lending. Mahajan started his career in India within the public accounting sector, including PwC. 

Steve is the Managing Partner of Shulman Ventures. He is the former chairman and CEO of Magellan Health Services, Inc. (NASDAQ: MGLN), where he spearheaded the company’s successful turnaround into the nation’s foremost specialty healthcare managed care company. He also led Prudential Healthcare through its major turnaround as the company’s chairman, president and CEO, culminating in the company’s successful sale to Aetna. Steve is the co-founder of Value Health, Inc., a NYSE managed care company, and also founded Internet HealthCare Group.